All In Biotech

Drug Trial Radar · NCT05044962

Kuwa Free! - Live Free!

Co-benefits of Co-delivery of Long-acting Antiretrovirals and Contraceptives

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Nov 26, 2021

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Moi Teaching and Referral Hospital; Indiana University; University of Nebraska; National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Sep 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 15 years, up to 24 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study investigators are conducting foundational pharmacokinetic (PK) and qualitative studies, among 15-24 years old (inclusive) adolescent girls and young women living with HIV (AGYWLHIV) already on oral antiretroviral therapy (ART) and virally suppressed, leading up to a hybrid type I effectiveness-implementation trial randomizing individual AGYWLHIV to receive long-acting (LA) injectable cabotegravir/rilpivirine vs. standard of care within one of Kenya's largest HIV treatment programs. The PK and qualitative studies will investigate potential issues arising from co-delivery and guide delivery of the effectiveness-implementation trial. The PK and qualitative studies will largely be conducted with a sentinel cohort of AGYWLHIV. Learning from this early LA ART use, the investigators will refine the procedures in the LA ART hybrid trial.

Conditions

  • HIV Infections
  • Contraception
  • Drug-drug Interaction

Interventions

  • Cabotegravir/ RilpivirineDrug

    For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin). For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine) CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709

  • Etonogestrel (ETG) implantDrug

    Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm

  • Intramuscular depo-medroxyprogesterone acetate (IM DMPA)Drug

    DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide

  • LevonorgestrelDrug

    Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm

  • NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimensDrug

    ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hormone concentrations with cabotegravir/rilpivirine use (Aim 1a)Time frame: 12 or 24 weeks after DMPA or implant initiation, respectively
  2. Number of participants with HIV viral suppression (Aim 2a)Time frame: 48 weeks after study enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Academic Model Providing Access to Healthcare (AMPATH) Moi Teaching And Referral Hospital (MTRH)

    Eldoret, Kenya, Kenya · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.